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ABSTRACT
Excess iron is tightly associated with tumorigenesis in
multiple human cancer types through a variety of
mechanisms including catalyzing the formation of
mutagenic hydroxyl radicals, regulating DNA replica-
tion, repair and cell cycle progression, affecting signal
transduction in cancer cells, and acting as an essential
nutrient for proliferating tumor cells. Thus, multiple
therapeutic strategies based on iron deprivation have
been developed in cancer therapy. During the past few
years, our understanding of genetic association and
molecular mechanisms between iron and tumorigenesis
has expanded enormously. In this review, we brieﬂy
summarize iron homeostasis in mammals, and discuss
recent progresses in understanding the aberrant iron
metabolism in numerous cancer types, with a focus on
studies revealing altered signal transduction in cancer
cells.
KEYWORDS Iron tumorigenesis, p53, Wnt, DNA repair,
cell cycle
INTRODUCTION: OVERVIEW OF IRON
AND CANCER
Iron serves important functions for mammalian cells as it is
involved in cell proliferation, metabolism and growth (Torti
and Torti, 2013). These processes are controlled by a variety
of iron- and heme-containing proteins, including enzymes
involved in DNA stability and cell cycle progression, mito-
chondrial enzymes involved in respiratory complexes, and
detoxifying enzymes such as peroxidase and catalase (Torti
and Torti, 2013; Zhang, 2014). Within the human body, iron
biologically exists in two oxidation states: ferrous iron (Fe2+)
and ferric iron (Fe3+) (Pantopoulos et al., 2012; Rouault,
2003). Iron has the property of gaining and losing electrons,
which enables it to participate in Fenton reaction (Pantopo-
ulos et al., 2012; Torti and Torti, 2013), in which Fe2+ donates
an electron in a reaction with hydrogen peroxide (H2O2) to
produce the hydroxyl radical (•HO) (Thomas et al., 2009), a
reactive oxygen species (ROS). Human body needs to
maintain systemic and cellular iron homeostasis by regulat-
ing iron acquisition, storage and efﬂux (Zhang, 2014). Iron
homeostasis is not only required for iron-containing protein
functions, but also critical for signal transduction and cellular
microenvironment (Xiong et al., 2014). The elevated iron
may result in the generation of ROS, which can damage
lipids, proteins and DNA, eventually leading to tumorigenesis
(Orrenius et al., 2011; Romero et al., 2014). It has been
reported that numerous types of cancers are implicated by
iron, such as lung cancer, breast cancer, prostate cancer,
colorectal cancer, hepatocellular cancer, pancreatic cancer
and hematological malignancies (Fig. 1) (Torti and Torti,
2013). On the other hand, iron deﬁciency caused anemia is
one of the major public health problems, particularly in chil-
dren and pregnant women (Denic and Agarwal, 2007; Miller,
2013). The recent studies also indicate that many patients
with cancer have anemia (Munoz et al., 2014), but the cause
is still to be determined.
Previous studies suggest that iron may function in tumour
initiation, tumour growth, tumour microenvironment and
metastasis (Mantovani et al., 2008; Sica et al., 2008). In
cancer cells, pathways involved in iron acquisition, trafﬁck-
ing, storage and regulation are all perturbed, suggesting that
iron metabolism is important for tumour cell survival (Torti
and Torti, 2013). Additionally, iron can also contribute to DNA
replication and repair processes, as well as cell cycle control
© The Author(s) 2014. This article is published with open access at Springerlink.com and journal.hep.com.cn










in cancer cells (Torti and Torti, 2013; Zhang, 2014). Signal-
ling through p53, Wnt, hypoxia-inducible factor (HIF), DNA
replication, repair and cell cycle progression pathways may
associate with altered iron metabolism in cancer (Torti and
Torti, 2013). Thus, decreasing cellular iron levels, targeting
iron metabolic pathways and iron-containing proteins may
provide new tools for cancer therapy.
IRON METABOLISM IN MAMMALS
Mammalian organisms have evolved sophisticated mecha-
nisms to regulate systemic and cellular iron balance
(Andrews and Schmidt, 2007; Pantopoulos et al., 2012).
Systemic iron metabolism
Generally, systemic iron regulatory processes include sev-
eral critical steps: (1) duodenal enterocytes acquire dietary
iron via divalentmetal transporter 1 (DMT1), also known as
solute carrier family 11 member 2 (SLC11A2), natural
resistance-associated macrophage protein 2 (NRAMP2), or
divalent cation transporter (DCT1) (Pantopoulos et al.,
2012). DMT1 localizes on the apical surface and functions
dependently on the reduction of Fe3+ to Fe2+ by duodenal
cytochrome b (DcytB) (Pantopoulos et al., 2012); (2) splee-
nic reticuloendothelial macrophages are responsible for iron
recycling from senescent red blood cells (Pantopoulos et al.,
2012); (3) iron exporter ferroportin (Fpn) releases iron oxi-
dized prior by hephaestin from Fe2+ to Fe3+ (Pantopoulos
et al., 2012); (4) transferrin (Tf) located on plasma mem-
brane acquires and delivers iron in the body (Pantopoulos
et al., 2012); and (5) hepatic hormone hepcidin controls
systemic iron trafﬁcking and iron efﬂux from cells by regu-
lating Fpn stability (Pantopoulos et al., 2012; Zhang, 2014).
Cellular iron metabolism
Cellular iron homeostasis is controlled by iron uptake at the
plasma membrane, eliciting balanced iron distributions
among cellular compartments and iron export (Valerio, 2007;
Zhang, 2014). Brieﬂy, most mammalian cells acquire iron via
Tf to form holo-Tf (Anderson and Vulpe, 2009; Dunn et al.,
2007), which further binds to transferrin receptor 1 (TfR1) to
form holo-Tf-TfR1 complex on the iron-consuming cell
membrane (Zhang, 2014). This complex is subsequently
internalized by receptor-mediated endocytosis (Lill et al.,
2012) and acidiﬁed in the endosome, facilitating the release
of Fe3+ from holo-Tf (Zhao et al., 2010). The six-transmem-
brane epithelial antigen of the prostate 3 (Steap3) reduces
Fe3+ to Fe2+, followed by transporting Fe2+ into the cyto-
plasm by DMT1 or transient receptor potential protein
(TRPML1) (Zhang et al., 2012). Later, the holo-Tf-TfR1
complex disassembles and apo-Tf recycles back to the cell
membrane to repeat another cycle (Pantopoulos et al.,
2012). Thereafter, the newly acquired iron stores into the
cytosolic “labile iron pool” (Gkouvatsos et al., 2012; Panto-
poulos et al., 2012). The excess cellular iron is either stored
in ferritin or exported via Fpn (Pantopoulos et al., 2012)
(Fig. 2). Moreover, two iron regulatory proteins, namely, IRP1
and IRP2, can post-transcriptionally regulate cellular iron
homeostasis (Zhang, 2014). In low iron condition, IRP1 and
IRP2 proteins speciﬁcally bind to iron-responsive elements
(IRE) in 3′- or 5′-UTR of the mRNA transcripts in TfR1, ferritin
heavy (H) chain, ferritin light (L) chain, or DMT1 (Zhang,
2014). The IRE-IRP system functions importantly in the
control of mammalian iron homeostasis (Pantopoulos et al.,
2012). Consequently, these iron regulatory proteins are
protected from degradation or their translations are inhibited
(Anderson and Vulpe, 2009; Dunn et al., 2007; Kaplan and
Kaplan, 2009; Muckenthaler et al., 2008).
IRON IS IMPLICATED IN A VARIETY OF CANCER
TYPES
Multiple cancer types have been widely reported to exhibit
abnormal iron contents or deﬁciency in iron uptake, utiliza-
tion and storage (Fig. 3). These cancers mainly include lung
cancer, breast cancer, prostate cancer, colorectal cancer,
hepatocellular cancer, pancreatic cancer, haematological
cancers, renal cell carcinoma and melanoma (Fig. 1) (Torti
and Torti, 2013).
Lung cancer
Lung cancers are generally categorized as small cell lung
cancer (SCLC) and non-small cell lung cancer (NSCLC)
(Vescio et al., 1990). During the past few years, hepcidin and




































Figure 1. Iron is implicated in multiple cancer types. These
cancers mainly include breast cancer, lung cancer, prostate
cancer, pancreatic cancer, melanoma, bladder cancer, hepato-
cellular cancer, colorectal cancer, gastric cancer and haemato-
logical cancers.
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several iron metabolism related proteins have been dem-
onstrated to associate with lung cancer genesis and tumor
cell proliferation (Xiong et al., 2014). Hepcidin expression is
increased in tumor tissue and serum of NSCLC patients, and
the increased serum hepcidin level is associated with lymph
node metastasis and tumor clinical stage of NSCLC (Xiong
et al., 2014). Iron related proteins, such as TfR1, H and L
subunits of ferritin protein, also exhibit increased levels in
lung cancer. In H1299 lung cancer cells, the induction of p53
decreases iron regulatory protein binding, leading to an
increase in both H and L subunits of ferritin protein, but a
decline of TfR1 level (Zhang et al., 2008). However, some
studies reported elevated expression of TfR1 in NSCLC
patients (Kukulj et al., 2010; Xiong et al., 2014). The elevated
serum ferritin levels were observed in NSCLC and SCLC
patients (Aleman et al., 2002; Kukulj et al., 2010; Yildirim
et al., 2007), and in patients with cancer during radiotherapy
(Koc et al., 2003). However, the expression of FPN in lung
cancer cells has not been reported.
IRP1 is responsible for cytosolic iron concentrations and
can post-transcriptionally regulate the expression of iron
metabolism genes to maintain cellular iron homeostasis
(Rouault, 2006). In cells with iron deﬁciency, IRP1 can bind
to IRE element of ferritin mRNA, enhancing iron uptake and
decreasing iron sequestration (Rouault, 2006). The tetracy-
cline-inducible overexpression of IRP1 or IRP1C437S mutant
results in misregulation of iron metabolism, highly active in
IRE-binding and increased TfR1 levels in human H1299 lung
cancer cells (Wang and Pantopoulos, 2002), but not altering
the growth properties of the H1299 cells in vitro (Wang and
Pantopoulos, 2002). However, overexpression of IRP1 or
IRP1C437S dramatically suppresses the growth of tumor xe-
nografts in nude mice (Chen et al., 2007), providing a direct
regulatory link between the IRE/IRP system and cancer. In
A549 lung cancer cells, IRP2 can regulate the expression of
TfR1 and ferritin by changing its own gene expression, and
thereby regulating iron metabolism (Cheng et al., 2014).

























Figure 2. Cellular iron metabolism in mammals. Apo-Tf binds ferric iron to form holo-Tf. Holo-Tf further forms a complex with TfR1
on the cell surface and the complex undergoes endocytosis. Acidifying by a proton pump, ferric iron is released from holo-Tf in the
endosome, where Steap3 reduces ferric iron to ferrous iron. Further, ferrous iron is transported across the endosomal membrane to
the cytosol by DMT1. DMT1 also facilitates dietary ferrous iron absorption in the plasma. The released apo-Tf is recycled back to the
plasma membrane to repeat another cycle. Newly acquired iron enters into cytosolic “labile iron pool” (LIP) (Pantopoulos et al., 2012).
The LIP is utilized by iron-sulfur clusters (Fe-S) proteins, hemoproteins, RNR and other iron-containing proteins, which localize in
different cellular compartments (Zhang, 2014). Cellular iron that is not utilized is either stored in ferritin or exported via ferroportin
(Pantopoulos et al., 2012).
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have recently been recognized to play a role in lung can-
cerogenesis and patients’ survival (Carpagnano et al.,
2012), implying the possibility of using them as an outcome
predictor of lung cancer.
Lipocalin-2 (LCN2), which is a member of the lipocalin
family and functions to ligate ferric siderophore-like mole-
cules, is involved in various cancers including lung cancer
(Shiiba et al., 2013), breast cancer (Yang et al., 2013),
ovarian cancer (Cho and Kim, 2009), colon cancer and
pancreatic cancer (Mannelqvist et al., 2012). The elevated
levels of LCN2 tightly associate with the malignance and
metastasis of cancer cells (Leng et al., 2009; Yang et al.,
2009). In lung cancer, LCN2 protein level increases signiﬁ-
cantly after X-ray irradiation (Shiiba et al., 2013), suggesting
that overexpression of LCN2 might contribute to radiation
resistance in cancer cells (Shiiba et al., 2013).
Breast cancer
Iron is strongly correlative to the risk of breast cancer
through many aspects such as interaction with estrogen,
disruption of lactoferrin, genetic variability in iron-related
oxidative stress pathways, and abnormal expression of iron
uptake or export genes (Torti and Torti, 2013).
The majority of breast cancers rely on supplies of estro-
gen to grow (Oh, 2002). Studies have revealed that estrogen
contributes to breast cancer in multifactorial ways, and iron is
suggested to interact with estrogen in two different ways
(Torti and Torti, 2013). Generally, low level of iron may
stimulate HIF1α activation and consequently promote angi-
ogenesis, whereas high level of iron may increase oxidative
stress (Torti and Torti, 2013). Recently, estrogen has been
considered to contribute to iron homeostasis by regulating
hepatic hepcidin expression directly through a functional
estrogen response element (ERE) in the promoter region of
hepcidin gene (Hou et al., 2012).
A unique correlation between iron and breast cancer is
mediated by lactoferrin (Torti and Torti, 2013). Lactoferrin is a
member of transferrin family and binds two ferric ions with
high afﬁnity (Torti and Torti, 2013; Ward et al., 2003). In
human breast cancer cells, the exogenous lactoferrin, or
adenovirus-mediated expression of lactoferrin can greatly
inhibit cell proliferation (Duarte et al., 2011; Torti and Torti,
2013). In mice bearing EMT6 breast cancer, the injection of
recombinant adenovirus containing lactoferrin can induce
apoptosis and inhibit tumor growth (Wang et al., 2011),
suggesting that lactoferrin has potential beneﬁt in treating
some breast cancers.
Several enzymes play critical roles in the formation and
reduction of iron-generated ROS, including NAD(P)H:qui-
none oxidoreductase 1 (NQO1), nitric oxide (NO) synthase
(NOS3) and heme oxygenase (HO) (Hong et al., 2007).
NQO1 is important for breast carcinogenesis as it functions
in the reduction of endogenous catechol estrogens (Hong
et al., 2007). In animals, the suppression of NQO1 increases
estradiol-dependent tumor formation (Hong et al., 2007;
Wyllie and Liehr, 1997). In mouse, the expression of NQO1



























Figure 3. Iron metabolism in normal cell and cancer cell. (A) The expression of Tf, TfR1, TfR2 and hepcidin is low, whereas the
expression of iron exporter gene FPN is high in normal cells, leading to a small pool of labile iron (Torti and Torti, 2013). (B) Cancer
cells exhibit increased expression of TfR1 and hepcidin, but low levels of FPN, leading to an increased labile iron pool (Torti and Torti,
2013).
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(Nrf2) through consensus regulatory sequence known as the
antioxidant response element (ARE) (Hong et al., 2007; Lin
et al., 2011). Interestingly, Nrf2 can induce ferritin-H and
ferritin-L gene expressions, leading to elevated cellular iron
(Hong et al., 2007; Iwasaki et al., 2013). NOS3 generally
functions to generate low levels of short-lived nitric oxide
(NO) by converting L-arginine to citrulline in endothelial tis-
sue (Hong et al., 2007). At low levels, NO acts as an anti-
oxidant by scavenging ROS and can bind to iron to reduce
redox cycling (Trachootham et al., 2008). The increased
expression of NOS3 has been detected in breast cancer,
which is positively associated with estrogen and progester-
one receptor status and negatively involved in histologic
grade and lymph node status (Martin et al., 2000; Vakkala
et al., 2000). HO also exhibits correlation with iron-related
carcinogenesis as it catalyzes the rate-limiting step in heme
degradation and provides cellular protection against oxida-
tive stresses (Choi and Alam, 1996; Stocker, 1990).
The abnormal expression of iron homeostasis related
genes are also widely examined in breast cancers. In human
breast cancer MCF-7 cells, the expression of iron transporter
genes including TfR1, DMT1 and FPN is altered (Jiang et al.,
2010). Compared to normal breast cells, the expression of
iron importer genes is increased, whereas the expression of
FPN is decreased in breast cancer cells to satisfy their
increased demands for iron (Jiang et al., 2010). Interestingly,
perturbations in ferritin levels are associated with breast
cancer progression toward a more advanced malignant
phenotype (Shpyleva et al., 2011). For instance, in human
breast cancer cell lines with an epithelial phenotype, such as
MCF-7, MDA-MB-361, T-47D and HCC70 cells, the
expression of ferritin-H, ferritin-L, Tf, TfR1, IRP1 and IRP2 is
decreased (Shpyleva et al., 2011). In contrast, the expres-
sion of these genes is commonly elevated in cells with an
aggressive mesenchymal phenotype, such as Hs-578T, BT-
549 and MDA-MB-231 cells (Shpyleva et al., 2011).
Additionally, LCN2 is a novel regulator of angiogenesis in
human breast cancer (Yang et al., 2013). LCN2 functions to
protect matrix metalloproteinase-9 (MMP-9) against degra-
dation, which further enhances its enzymatic activity and
facilitates angiogenesis and tumor growth (Fernandez et al.,
2005). Overexpression of LCN2 in MCF7 breast cancer cells
increases the expression of vascular endothelial growth
factor (VEGF), a key angiogenic activator (Yang et al., 2013).
The LCN2-induced VEGF is mediated through HIF1α and
that LCN2 regulates HIF1α through extracellular signal-reg-
ulated kinase (Erk) (Yang et al., 2013). However, some
studies reported that inhibition of LCN2 results in breast
tumorigenesis in two different mouse models (Berger et al.,
2010; Leng et al., 2011).
Prostate cancer
Prostate cancer is one of the most commonly diagnosed
malignancies in men (Al Robaian et al., 2014). Iron also
exhibits relevance to prostate cancer, including FPN level
reduction (Chen et al., 2014), redox-sensitive transcription
factor (NF-κB) activation (Ornstein and Zacharski, 2007), the
HIF1α-dependent pathway activation (Tsui et al., 2013), the
association between heme iron intake and prostate cancer
risk (Jakszyn et al., 2012), and high level of β2-microglobulin
(β2-M) in patients with prostate cancer (Josson et al., 2013).
In prostate tumors, the Fpn protein level is signiﬁcantly
reduced by comparison with adjacent tissues, indicating a
crucial role of Fpn in prostate tumor growth through con-
trolling iron concentration (Chen et al., 2014). Conversely,
inhibition of myeloid zinc-ﬁnger 1 (MZF-1) expression, an
oncogene or a tumor suppressor, can lead to decreased Fpn
level, enhancing tumor cell growth (Chen et al., 2014).
Treatment of the human prostate cancer cell line PC-3
with iron in the form of ferric nitrilotriacetate (FeNTA), but in
the absence of added transferrin, results in stimulation of
intracellular reactive oxygen intermediates (ROI) production,
NF-κB activation and increasing urokinase-type plasmino-
gen activator (uPA) expression (Ornstein and Zacharski,
2007). These results imply that non-transferrin-bound iron
(NTBI) may indirectly promote prostate cancer growth and
metastasis (Ornstein and Zacharski, 2007). In PC-3 and
LNCaP human prostate carcinoma cells, hypoxia dysregu-
lates the expressions of lactate dehydrogenase A (LDHA),
fatty acid synthase (FASN) and mitochondrial aconitase
(mACON) genes (Tsui et al., 2013). In which, the hypoxia-
induced mACON gene expression is via the HIF1α-depen-
dent and iron-dependent pathways (Tsui et al., 2013).
Heme iron can promote endogenous production of NOCs
(nitrosocompounds) and catalyze free radical formation,
leading to oxidative cell damage (Jakszyn et al., 2012). The
endogenous and exogenous dietary nitrosamines and heme
iron intake have potential effect on prostate cancer risk
(Jakszyn et al., 2012). Prostate cancer patients with bone
metastasis exhibit elevated expression of β2-microglobulin
(β2-M), which is a cell membrane protein (Josson et al.,
2013). Previous studies have demonstrated that β2-M
interacts with hemochromatosis protein (HFE), preventing
excessive iron uptake (Josson et al., 2013). The β2-M/HFE
complex is required for cancer development and bone
metastasis (Josson et al., 2013). Genetic deletion of β2-M or
HFE in prostate cancer cells exhibits sensitivity to radiation
in vitro and in vivo (Josson et al., 2013).
Colorectal cancer
Studies have demonstrated that iron confers an increased
risk for colorectal cancer (CRC). Commonly, increased cel-
lular iron exposure is associated with CRC risk (Pusatcioglu
et al., 2014). Hepcidin, a peptide hormone synthesized
mainly in the liver, functions to inhibit iron transport by
binding to Fpn (Rossi, 2005). Inappropriately elevated serum
hepcidin may reduce duodenal iron absorption, which further
increases colonic adenocarcinoma iron exposure in CRC
patients (Pusatcioglu et al., 2014). Hereditary hemochro-
matosis, a genetic disorder of iron overload, generally
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harbors inappropriately elevated intestinal iron absorption
(Emanuele et al., 2014). In HFE-associated hereditary he-
mochromatosis, mutations in the HFE gene disrupt the
synthesis of hepcidin (Osborne et al., 2010). Decreased
hepcidin levels result in increased release of iron from
intestinal cells and macrophages, elevating plasma trans-
ferrin saturation and causing deposition of iron in the liver
and other tissues (Osborne et al., 2010). HFE C282Y
homozygotes have twice the risk of colorectal and breast
cancer relative to those individuals without the C282Y variant
hepcidin (Osborne et al., 2010).
The Apc (adenomatous polyposis coli) gene is the most
commonly mutated tumor suppressor gene in sporadic
colorectal cancer (Armaghany et al., 2012). After Apc dele-
tion, TfR1 and DMT1 protein levels are rapidly induced
(Radulescu et al., 2012). Conversely, restoration of APC
reduces cellular iron due to repression of these two proteins
(Radulescu et al., 2012). Deﬁciency of luminal iron signiﬁ-
cantly suppresses murine intestinal tumorigenesis, whereas
increased luminal iron strongly promotes tumorigenesis
(Radulescu et al., 2012). These results deﬁnitively delineate
iron as a potent modiﬁer of intestinal tumorigenesis (Rad-
ulescu et al., 2012).
Cellular iron uptake proteins such as DMT1 and TfR1 are
up-regulated in CRC, whereas iron export proteins such as
Fpn and hephaestin (HEPH) are down-regulated (Xue and
Shah, 2013). In mouse models of colon cancer, iron-enri-
ched diets increase the development of colon tumors
(Tammariello and Milner, 2010). Moreover, hypoxia-inducible
factor 2α (HIF2α) activation can promote colorectal cancer
progression by dysregulating iron (Xue et al., 2012).
Hepatocellular cancer
The liver is the most frequently affected organ by iron
overload because iron is mainly stored in hepatocytes
(MacKenzie et al., 2008). Hepatocellular carcinoma (HCC)
commonly develops in patients with underlying hereditary
hemochromatosis (HH) (Tan et al., 2009). Patients with HCC
generally contain elevated iron in their livers, indicating the
critical role of iron in stimulation of carcinogenesis (Kowdley,
2004). The wild-type HFE protein can form a complex with
TfR, and two HFE mutations (C282T and H63A), and it also
has been found to increase the afﬁnity to the TfR (Beckman
et al., 2000).
By using immunohistochemistry, the expression of TfR1
and TfR2 is signiﬁcantly higher in human HCC tissues than
in adjacent non-tumor tissues (Sakurai et al., 2014), sug-
gesting that TfR1 and TfR2 are expressed in response to
iron deﬁciency during liver carcinogenesis (Sakurai et al.,
2014). Interestingly, in tumorous tissues from 24 HCC
patients with chronic HBV infection, iron staining assay result
by Perls’ Prussian blue was negative, whereas excess iron
deposits were present in 17 of the 24 adjacent non-tumorous
liver tissues (Tan et al., 2009). The expression of iron-regu-
latory genes, including hepcidin, TfR2, Tf and IRP1 were
signiﬁcantly down-regulated in the tumorous tissues in
comparison to the adjacent non-tumorous liver tissues (Tan
et al., 2009). The proteomic and genomic evidences indi-
cated that ferritin-L was suppressed in HCC (Park et al.,
2002). The suppressed level of ferritin-L in HCC may be
resulted from modiﬁcation of IRPs, which may tightly bind to
the IRE element of a target gene, thereby blocking de novo
translation of ferritin-L (Park et al., 2002).
Pancreatic cancer
Pancreatic cancer is one of the most fatal cancers in adult
men and women (Bracci, 2012). Obesity is a modiﬁable risk
factors associated with increased risk of pancreatic cancer
(Bracci, 2012). Evidence suggests that obesity is associated
with higher hemoglobin and ferritin concentrations (Hama-
lainen et al., 2012). Ferritin is detected at higher levels in the
sera of many patients with pancreatic cancer (Kalousova
et al., 2012). Additionally, labile iron has been implicated in
both the pathogenesis and treatment of pancreatic cancer
(Moser et al., 2013). In human pancreatic cancer cell line
MIA PaCa-2, pharmacological ascorbate and irradiation
have been shown to increase the labile iron in tumor
homogenates (Moser et al., 2013). Heme-iron is associated
with increased pancreatic cancer risk in female smokers
(Molina-Montes et al., 2012).
An elevated expression of LCN2 has been observed in
pancreatic cancer (Leung et al., 2012). In two pancreatic
ductal adenocarcinoma cell lines (BxPC3 and HPAF-II), the
downregulation of LCN2 signiﬁcantly reduces attachment,
invasion and tumour growth in vivo, but not proliferation or
motility (Leung et al., 2012). In contrast, the overexpression
of LCN2 in PANC1 cells signiﬁcantly increases invasion,
attachment and tumor growth (Leung et al., 2012). LCN2
promotes the expression of VEGF and HIF1α, which con-
tributes to the enhanced vascularity (Leung et al., 2012).
These results indicate that LCN2 is critical for the malignant
progression of pancreatic ductal carcinoma.
Haematological malignancies
Haematological cancers include various types of blood
cancers and related diseases such as acute and chronic
leukaemias, myeloproliferative disorders, myelodysplastic
syndromes and aplastic anemia (Koreth and Antin, 2010).
Haematologic disorders commonly associate with iron
overload due to increased iron absorption and hepcidin
suppression (Koreth and Antin, 2010).
Patients with multiple myeloma (MM) have increased
serum hepcidin, which inversely correlates with hemoglobin,
suggesting that hepcidin contributes to MM-related anemia
(Maes et al., 2010). Further studies revealed that hepcidin is
induced by increased bone morphogenetic protein 2 (BMP2)
(Maes et al., 2010). Hepcidin is upregulated by interleukin-6
(IL-6) in Hodgkin’s lymphoma (HL) patients in comparison to
controls (Hohaus et al., 2010). Elevated levels of hepcidin in
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HL correlate with iron restriction and contribute to anemia
(Hohaus et al., 2010). Additionally, hepcidin levels show a
positive correlation with ferritin and an inverse correlation to
iron and iron-binding capacity (Hohaus et al., 2010).
Two TfR1 antibodies, namely, 3TF12 and 3GH7, have
been identiﬁed to exhibit abilities against tumors whose
proliferation relies on high levels of TfR1 and iron uptake,
such as acute lymphoid and myeloid leukemias (Crepin
et al., 2010). Chelation of intracellular iron with the antifungal
agent ciclopirox olamine (CPX) induces cell death in leuke-
mia and myeloma cells (Eberhard et al., 2009).
IRON AND SIGNAL PATHWAYS IN CANCER
A variety of signal pathways are activated in different types
of cancer cells, such as p53 pathway, Wnt pathway, HIF
pathway, DNA replication and repair pathway, cyclins and
cell cycle regulation, EGF pathway, AKT pathway and VEGF
pathway. Interestingly, it has been found that iron is involved
in most of these pathways (Fig. 4).
Iron and p53
Iron status inﬂuences p53 activity and antioxidant response
by modulating the expression of MDM2 (mouse double
minute gene 2) (Dongiovanni et al., 2010). In mouse hepa-
tocytes and rat liver, iron status has been identiﬁed to reg-
ulate MDM2, which is associated with speciﬁc changes in
p53 expression (Dongiovanni et al., 2010). MDM2 functions
as a predominant negative regulator of p53, and it controls
p53 activity and degradation through ubiquitination (Don-
giovanni et al., 2010). Further, iron dependent regulation of
MDM2/p53 has been conﬁrmed in human monocytes
(Dongiovanni et al., 2010). In which, the manipulation of iron
pool leads to modulation of p53 target genes involved in the
antioxidant response and apoptosis (Dongiovanni et al.,
2010). Iron status inﬂuences p53 ubiquitination and degra-
dation rate, and the MDM2 inhibitor nutlin increases p53
levels in iron-depleted cells (Dongiovanni et al., 2010).
Recently, iron metabolism has been revealed to regulate
p53 signaling pathway through direct heme-p53 interaction
and modulation of p53 localization, stability and function
(Shen et al., 2014). Iron can directly affect the expression of
p53, which is downregulated during iron excess (Shen et al.,
2014). Iron polyporphyrin heme directly binds to p53 protein
via the C-terminal CP motif (CACP) (Shen et al., 2014),
which is a highly conserved DNA-binding domain (DBD) in
eukaryotic p53 proteins (Shen et al., 2014). The binding
leads to disruption of p53-DNA interactions, triggering both
nuclear export and cytosolic degradation of p53 (Shen et al.,
2014).
Iron and Wnt pathways
There are three well-characterized Wnt signaling pathways,
including Wnt/β-catenin pathway, noncanonical planar cell
polarity (PCP) pathway and noncanonical Wnt/calcium
pathway (von Maltzahn et al., 2012). Excessive signaling
from the Wnt pathways has been implicated in the devel-
opment of numerous types of cancers (MacDonald et al.,
2009; von Maltzahn et al., 2012). Interestingly, previous
studies have revealed a critical requirement of iron in Wnt
signaling, and iron chelation serves as an effective mech-
anism to inhibit Wnt signaling in humans (Song et al., 2011).
A series of acyl hydrazones can bind iron in vitro and in
intact cells, and the chelating activity is required for abro-
gating Wnt signaling and blocking the growth of colorectal
cancer cell lines with constitutive Wnt signaling (Song et al.,
2011). In addition, multiple iron chelators, including desfer-
rioxamine (DFO), deferasirox and ciclopirox olamine, func-
tion similarly to inhibit Wnt signaling and cell growth (Song
et al., 2011). In an iron-induced mouse model of kidney
cancer, an aberrant Wnt signalling was also examined (Torti
and Torti, 2013). A soluble iron salt, namely, ferric nitrilotri-
acetate (FeNTA), can induce nephrotoxicity and kidney
cancer in rats and mice models, suggesting that the acti-
vation of Wnt signalling may be a common pathway through
which iron contributes to malignant progression (Torti and
Torti, 2013).
Clearly, iron has important effects on Wnt signaling
pathway, and iron mainly contributes to Wnt signaling path-
way through the following two aspects: (1) it augments Wnt
signalling in cells with aberrant APC or β-catenin, and (2) it
downregulates E-cadherin which is essential for the induc-
tion and maintenance of polarized and differentiated epi-
thelia in an APC-independent manner (Torti and Torti, 2013).
These effects of iron on Wnt signalling may provide insight
into the mechanism of iron exacerbating intestinal tumori-




































Figure 4. Signal pathways in cancers caused by iron
excess. A variety of signal pathways are activated in multiple
cancer types. These pathways mainly include p53 pathway, Wnt
pathway, HIF pathway, DNA replication and repair pathway,
cyclins and cell cycle regulation, and oxidative stress pathways.
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Iron and HIF pathways
Iron levels can also regulate hypoxia-inducible factor-α
(HIFα) proteins, which are transcription factor subunits that
are critical for the regulation of hypoxia response (Torti and
Torti, 2013). There are three HIFα family members: HIF1α,
HIF2α and HIF3α (Peyssonnaux et al., 2007). These sub-
units can form heterodimers with HIF1β (also known as
ARNT), respectively, to function as the HIF transcription
factors (Keith et al., 2012), which transcriptionally induce
numerous genes responded to hypoxia, including vascular
endothelial growth factor A (VEGFA), glucose transporter 1
(GLUT1; also known as SLC2A1), erythropoietin (EPO) and
survivin (also known as BIRC5) (Torti and Torti, 2013). These
HIFα subunits are posttranslationally regulated by iron-
dependent prolyl-hydroxylases (PHD proteins) (Hewitson
et al., 2003; Torti and Torti, 2013).
HIF protein activities are induced in many types of
tumours, which are generally associated with tumour cell
growth and progression (Torti and Torti, 2013). In cancer
cells, HIF can induce the expression of a variety of iron
metabolism genes, contributing to iron accumulation in
cancer cells. For instance, HIF1α induces TfR1 expression,
resulting in increasing iron uptake (Lok and Ponka, 1999;
Tacchini et al., 1999). HIF1α induces the expression of
ceruloplasmin, which is a ferroxidase enzyme to oxidize iron,
facilitating the loading of iron onto Tf (Mukhopadhyay et al.,
2000). Moreover, HIF1α also induces HO1 expression,
leading to the degradation of heme into biliverdin, carbon
monoxide and iron; as a result, which enables iron to be
recycled (Lee et al., 1997). Additionally, HIF2α induces the
expression of FPN, DMT1 and DCYTB in enterocytes to
promote systemic iron uptake (Peyssonnaux et al., 2007;
Torti and Torti, 2013).
Iron, DNA replication, repair and cell cycle progression
Defects in genes required for DNA replication and repair
always cause genetic instability and are associated with
multiple human cancer types (Preston et al., 2010). Inter-
estingly, a variety of iron-containing proteins are involved in
DNA replication and repair processes, such as DNA poly-
merases, DNA helicases, and the small subunit of ribonu-
cleotide reductase (RNR) (Zhang, 2014). The eukaryotic
DNA synthesis is generally performed via three conserved
polymerases: Pol α, Pol δ and Pol ε (Miyabe et al., 2011). All
of these DNA polymerases contain a Fe-S cluster in their
active holoproteins (Zhang, 2014). DNA helicase and heli-
case-nuclease enzymes, including Xeroderma pigmentosum
group D-complementing protein (XPD; also known as
ERCC2), Fanconi anemia group J protein (FancJ), a mem-
ber of the DEAD/DEAH subfamily of helicase ChlR1, regu-
lator of telomere elongation helicase 1 (RTEL1) and DNA
replication helicase 2 (Dna2), contain a conserved Fe-S
cluster in their N-terminus, which is essential for helicase
activities (Wu and Brosh, 2012). RNRs utilize radical
chemistry to reduce ribonucleotides to synthesize deoxyri-
bonucleotides (dNTPs), thereby generating the necessary
precursors of DNA replication and repair (Zhang, 2014).
Imbalanced dNTP pools are associated with increased DNA
mutations, DNA strand breaks, and even cell death by
enhancing misincorporation of nucleotides and by inhibiting
DNA polymerase functions (Kumar et al., 2010; Zhang et al.,
2014). The catalytic activity of RNR is dependent on a di-
nuclear iron site in the M2 subunit (RRM2) (Aye et al., 2014).
Moreover, mammalian cells harbor a p53-inducible RRM2
subunit (p53R2, also known as RRM2B), which is induced in
response to DNA damage (Torti and Torti, 2013). Interest-
ingly, p53R2 is sensitive to iron chelation, thus it represents a
target for iron chelation therapy in tumours with wild-type p53
(Torti and Torti, 2013).
Cells progress through the cell cycle unchecked may
eventually result in malignant tumors (Tenga and Lazar,
2014). Iron is a major regulator of cell cycle by inhibiting
either the formation or activities of the cyclin and cyclin-
dependent kinase complexes (Zhang, 2014). Intracellular
iron disruption by chelators leads to cell cycle arrest, par-
ticularly in G1 and S phases (Fu and Richardson, 2007;
Siriwardana and Seligman, 2013). In many types of cancers
such as sarcomas, colorectal and melanomas, cyclin D
overproduction is observed (Burandt et al., 2014; Wang
et al., 2014). Cyclin D1 associates with cyclin-dependent
kinase 4 (CDK4) and CDK6 to regulate G1/S progression by
phosphorylating retinoblastoma tumor suppressor protein
(RB), which in turn releases the transcription factor E2F from
RB (Torti and Torti, 2013).
Iron and other pathways
Iron is also involved in AKT pathway and VEGF pathway in
cancer cells. Iron oxide nanoparticles (Fe2O3 NPs) can
mediate cytotoxicity via PI3K/AKT pathway, in which Fe2O3
NPs induce cellular damage and a natural ﬂavonoid quer-
cetin plays a protective role in Fe2O3 NPs induced cytotox-
icity and apoptotic death (Sarkar and Sil, 2014). Iron-
saturated lactoferrin stimulates cell cycle progression
through PI3K/Akt pathway in MCF-7 cells (Lee et al., 2009).
Vascular endothelial growth factor (VEGF) is a target of HIF,
and its expression is induced in cells exposed to hypoxia
(Forsythe et al., 1996). Thus, VEGF pathway is possibly
involved in iron-mediated carcinogenesis.
THERAPEUTIC STRATEGIES BASED ON IRON
DEPRIVATION
Elevated cellular iron may cause tumorigenesis, therefore
decreasing iron level and targeting iron-containing proteins
such as RNR have been developed as efﬁcient strategies in
chemotherapy. Numerous iron chelators, such as DFO,
triapine, deferiprone, deferasirox and tachpyridine, have
been preclinically or clinically used as anticancer agents
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(Torti and Torti, 2013). Of them, DFO and triapine are the
most common iron chelators used in cancer therapy. DFO
has antiproliferative effect both in vitro and in vivo, which is
mediated by its depleting effect on intracellular iron pools
(Dayani et al., 2004). However, the clinical efﬁciency of DFO
is limited by its poor membrane permeability and a very short
half-life in the bloodstream (Chaston and Richardson, 2003;
Lovejoy and Richardson, 2003). Triapine exhibits wide-
spectrum antitumor activity and cytotoxicity (Buss et al.,
2003; Yu et al., 2006). Studies suggest that the cytotoxicity
of triapine involved multiple mechanisms, such as by forming
complexes with both Fe2+ and Fe3+, and by inhibiting both
RRM2 and p53R2 (Enyedy et al., 2011; Zhang et al., 2014).
The Fe2+-triapine can react with O2 to produce reactive
oxygen species (ROS) (Richardson et al., 2009).
Moreover, some strategies that generate single-chain
antibodies targeted towards TfR1 also have been developed
(Crepin et al., 2010; Torti and Torti, 2013). TfR1 is mainly
targeted in two different ways: (1) delivering therapeutic
molecules into malignant cells, and (2) blocking the natural
function of the receptor leading directly to cancer cell death
(Daniels et al., 2012). Numerous types of anti-cancer drugs
targeted TfR1 have been developed, such as a variety of
anti-TfR antibodies (HB21, 454A12, B3/25, OKT9, 7D3,
7579 and 42/6) (Daniels et al., 2012), and multiple tumor-
targeting ligands which are responsible for the delivery of
numerous antitumour cytotoxics (TF-doxorubicin, TF-cis-
platin, TF-chlorambucil, TF-ricin A chain and TF-diptheria
toxin) (Torti and Torti, 2013). Some studies have obtained
promising results for the treatment of a variety of cancers via
cytotoxicity induced by the direct inhibition of TfR1 function
by its monoclonal antibodies (Daniels et al., 2012). These
tumor-targeting ligands can be delivered into cancer cells,
causing cytotoxic effects including growth inhibition and/or
induction of apoptosis in a variety of malignancies in vitro
and in vivo (Daniels et al., 2012).
CONCLUSION
Collectively, altered iron metabolism is a key hallmark of
cancer. Iron diversely functions in tumor microenvironment,
cancer initiation, progression and metastasis. A variety of
signal pathways are activated by iron in cancer cells, and the
expression of numerous iron metabolism genes is aberrant
in malignant tumors, suggesting the fundamental roles of
iron in developing cancer. Although great progresses have
been made in the previous studies, the detailed under-
standings on the mechanisms of iron homeostasis regula-
tion, iron-containing protein functions, and signal
transduction involved in iron in cancer cells are still required
to further explore.
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